Exploring Key Insights of the Monoclonal Antibodies (MAbs) Market: Growth Prospects, Emerging Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the monoclonal antibodies (mabs) market right now?
The market size for monoclonal antibodies (MAbs) has witnessed swift expansion in the past few years. Its growth is projected to elevate from $234.37 billion in 2024 to $261.66 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.6%. The historical growth rate can be credited to several factors such as widespread chronic ailments, escalations in R&D investment, an increase in mabs recognition, and the rise in the aging population.
How fast Is the monoclonal antibodies (mabs) market expected to grow, and what’s its future value?
In the coming years, a swift expansion is anticipated for the monoclonal antibodies (MAbs) market size. By 2029, it is projected to surge to $424.24 billion, marking a compound annual growth rate (CAGR) of 12.8%. The projected growth within this period can be correlated to factors such as increased therapeutic indications, advancement in personalized medicine, the rise of biosimilars and generics, combination therapies, preparedness for pandemics, and robust investment in biopharmaceuticals. Key trends predicted for this period involve progressions within immunotherapy, adoption of subcutaneous administration, development of next-generation antibodies and subcutaneous formulations, integration of digital health, and advancements within the biotechnology sector.
Get your monoclonal antibodies (mabs) market report here!
https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp
What are the leading drivers of growth in the monoclonal antibodies (mabs) market?
The growth of the monoclonal antibody market is being propelled by the rising availability of cost-effective biosimilar monoclonal antibodies. These biosimilars are designed to help control escalating healthcare costs and address the economic strain on patients and governments to lower drug prices and expand treatment availability. They mimic the properties of an already approved biological drug and are therefore classified as pharmaceuticals. Interestingly, a biosimilar monoclonal antibody is 20%-25% less expensive than the original biologic drug. This is attributed to the minimal number of clinical trials required for a biosimilar as compared to the original biologic drug, thereby reducing the overall cost. In a significant development, the introduction of a new biosimilar policy titled ‘Guidelines on Similar Biologics’ by the Central Drugs Standard Control Organization (CSDCO) in India is projected to considerably enhance the Indian biosimilar drugs sector.
What are the key segments defining the monoclonal antibodies (mabs) market?
The monoclonal antibodies (MAbs) market covered in this report is segmented –
1) By Source: Murine, Chimeric, Humanized, Human
2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications
3) By End Users: Hospitals, Private Clinics, Research Institute
Subsegments:
1) By Murine: Fully Murine MAbs, Murine-Derived MAbs
2) By Chimeric: Chimeric MAbs With Murine Variable Regions, Chimeric MAbs With Human Constant Regions
3) By Humanized: Humanized MAbs With Minor Murine Components, Fully Humanized MAbs
4) By Human: Fully Human MAbs, Engineered Human MAbs
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp
Who are the key players steering the development of the monoclonal antibodies (mabs) market?
Major companies operating in the monoclonal antibodies (MAbs) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc
What emerging trends are influencing the growth of the monoclonal antibodies (mabs) market?
Recent years have seen a wealth of strategic actions within the monoclonal antibody market. Market leaders are frequently expanding their portfolio and reach by acquiring start-ups and middle-tier companies. They are also leveraging strategic partnerships, acquisitions, and collaborative agreements to amplify their product and service offerings. As an illustration, Sanofi S.A., a France-based pharmaceutical and healthcare giant, announced a partnership in March 2022 with Seagen Inc., an American company specializing in pioneering powerful treatments based on monoclonal antibodies for cancer. This collaboration aims to employ the unique monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies of both companies to devise, develop, and distribute ADCs targeting up to three types of cancer. Additionally, Germany’s Boehringer Ingelheim, a pharmaceutical company grounded in research, declared its association with MabGenesis, Inc., a Japanese biopharmaceutical company innovating in the therapeutic monoclonal antibody drugs sector. This union will lead to the discovery and development of novel monoclonal antibodies to treat various conditions and set strategic R&D tactics. The industry’s companies are steadily adjusting to their portfolios and seeking profitable inorganic growth avenues. The rising interest in mergers and acquisitions (M&As) can be attributed to robust corporate balance sheets, liquid debt markets, and ongoing favourable international interest rates.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2554
Which regions are most influential in expanding the monoclonal antibodies (mabs) market?
North America was the largest region in the monoclonal antibodies (MAbS) market in 2024. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Browse Through More Similar Reports By The Business Research Company:
Conjugated Monoclonal Antibodies Global Market Report 2024
Research Antibodies and Reagents Global Market Report 2024
Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
